Omzo vs IVIM Health: Compare Compounded Semaglutide Plans
Quick verdict: For clinician-guided compounded options and the ability to receive prescriptions for branded GLP-1, Omzo emphasizes personalized, licensed-provider review and compounded semaglutide starting at $179. IVIM Health emphasizes a clinician-structured protocol, third-party ratings, and compounded GLP-1 starting at $75/month with a free month code. Choose based on whether you prioritize branded-prescription options and clinician networks (Omzo) or third-party ratings and a proprietary protocol (IVIM Health).
Explore Omzo clinician-guided plans
Key differences at a glance: pricing, medication options, clinical approach
The most distinctive supported differences between Omzo and IVIM Health are: starting pricing and pricing model, medication options including whether providers may write prescriptions for branded medications, clinical program approach and protocol claims, and third-party satisfaction signals. Both offer compounded GLP-1 but each platform emphasizes different features and claims.
1. Pricing and membership models
Omzo: Semaglutide starts at $179 according to the source. IVIM Health: published starting price information shows $75/month and program pricing details include a program fee; IVIM also advertises a free month membership via code GIFT75 and a no-obligation free consultation valued at $75. The two providers use different pricing signals: Omzo lists a starting price per its clinician-guided offerings, while IVIM lists monthly rates and membership promotions.
See IVIM Health membership and code
2. Medication options and regulatory notes
Omzo: Connects users with licensed medical providers who may prescribe compounded medications or, alternatively, write prescriptions for branded FDA-approved medications; Omzo states compounded medications offered are not FDA-approved. IVIM Health: Offers compounded semaglutide and tirzepatide, and the source specifies these compounded drugs are not FDA-approved. Both sources preserve the regulatory qualifier that compounded drugs have not been reviewed by the FDA for safety, effectiveness, or quality.
3. Clinical approach, protocols, and outcome claims
Omzo: Emphasizes clinician-guided plans reviewed by licensed U.S. providers and personalized GLP-1 care. IVIM Health: Promotes a proprietary GLP-1 ID protocol and cites internal or published retrospective studies claiming Ivim patients following the protocol lost more weight compared to a published clinical GLP-1 trial; the source notes this is not a head-to-head study and the 40% or 46% figures are protocol or internal claims and not independent randomized trials. Both platforms state providers determine eligibility and prescribe after clinician review.
4. Third-party trust signals and patient experience
Omzo: Highlights clinician-reviewed plans and patient anecdotes captured on its landing page. IVIM Health: Highlights unusually strong third-party verification with a 4.9-star rating on both Google and Trustpilot and cites two retrospective observational studies published in Obesity Pillars as sources for outcomes data. These are positioned as differentiators in satisfaction and published observational results, with IVIM noting those studies are not randomized controlled head-to-head trials.
| Criteria | Omzo | IVIM Health |
|---|---|---|
| Starting price | Semaglutide starting at $179 | Compounded semaglutide $75/mo; free month code GIFT75 |
| Medication types offered | Compounded semaglutide & tirzepatide; providers may write prescriptions for branded meds | Compounded semaglutide & tirzepatide only (compounded) |
| Regulatory note | Compounded medications are not FDA-approved | Compounded medications are not FDA-approved |
| Clinical approach | Clinician-guided plans reviewed by licensed U.S. providers | Proprietary GLP-1 ID protocol with clinician-guided titration |
| Third-party ratings and studies | Patient experiences and clinician network emphasized | 4.9-star ratings on Google and Trustpilot; two retrospective studies cited |
How to pick between Omzo and IVIM Health
If you want the option that explicitly notes providers may write prescriptions for branded medications and you prefer a platform that emphasizes clinician-reviewed plans, Omzo may fit your needs. If you weight third-party satisfaction scores heavily and prefer a platform marketing a structured proprietary protocol with published retrospective outcomes, IVIM Health may be more appealing. Both sites state compounded medications are not FDA-approved and both require clinician evaluation before prescribing.
Review IVIM Health protocol and ratings
Compare Omzo plans and starting price
Final notes and choose guidance
Both Omzo and IVIM Health provide clinician-guided compounded GLP-1 care with explicit regulatory notes that compounded medications are not FDA-approved. Neither provider guarantees results and both require clinician review and prescriptions where applicable. The primary keyword here is Omzo vs IVIM Health and the comparison above focuses on the supported differences from each source.
Choose Omzo if you want clinician-guided plans reviewed by licensed U.S. providers and the option for providers to prescribe branded medications in addition to compounded options.
Choose IVIM Health if you prioritize a platform with dual 4.9-star third-party ratings, a proprietary GLP-1 ID protocol, and promotional offers such as a free month code GIFT75 and a no-obligation free consultation.